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Abstract 
Dissolvable microneedles can be employed to deliver DNA to antigen presenting cells within 
the skin. However, this technology faces two main challenges: the poor transfection efficacy 
of pDNA following release from the microneedle matrix, and the limited loading capacity of 
the micron-scale devices. Two-tier delivery systems combining microneedle platforms and 
DNA delivery vectors have increased efficacy but the challenge of increasing the loading 
capacity remains. This study utilised lyophilisation to increase the loading of RALA/pDNA 
nanoparticles within dissolvable PVA microneedles. As a result, delivery was significantly 
enhanced in vivo into an appropriate range for DNA vaccination (~50 μg per array). 
Furthermore, modifying the manufacturing process was not detrimental to the microneedle 
mechanical properties or cargo functionality. It was demonstrated that arrays retained 
mechanical and functional stability over short term storage, and were able to elicit gene 
expression in vitro and in vivo. Finally, treatment with this novel formulation significantly 
retarded the growth of established tumours, and proved superior to standard intramuscular 
injection in a preclinical model of cervical cancer. 
 
Key Words: DNA Vaccine; Microneedle; RALA; Lyophilisation; Nanoparticle; Cervical 
Cancer  
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1. Introduction 
The advantages of DNA vaccines include: elicitation of potent therapeutic and prophylactic 
immune responses;
[1]
 high stability leading to lower production and storage costs;
[2]
 and 
flexibility of design through control of the nucleotide sequence allowing multiple antigens 
and/or adjuvants within one plasmid.
[3,4]
 Despite DNA vaccines demonstrating good safety 
and tolerability, the induction of meaningful immune responses through simple injection has 
proven difficult to achieve in human trials, because of the extra- and intracellular biological 
barriers to gene delivery.
[5,6]
 Microneedles (MNs), consist of multiple sharp projections less 
than 1000 µm in length secured to a baseplate and can pierce the stratum corneum (SC), 
creating transient pores for delivery of genetic cargo to the viable epidermis and dermis, 
overcoming such extracellular barriers.
[7]
 These are ideal sites for vaccine delivery due to the 
high population of resident antigen presenting cells (APCs), (such as epidermal Langerhan 
Cells [LCs] and dermal dendritic cells [DCs]), which are essential to the induction of CD8+ T 
cells, the effectors of the adaptive immune system that can destroy antigen expressing target 
cells.
[8,9]
 The dermal layers of the skin also harbour an extensive lymph network, providing 
drainage for activated DCs and enabling rapid T cell priming.
[10]
 Furthermore, delivery via 
MN increases the chances of transfecting both APC and non-APCs compared to a single 
needle injection.
[11]
 Other advantages of MN include self-application,
[12]
 minimal storage 
requirements,
[13]
 and pain-free delivery thereby increasing patient acceptability.
[14] 
To date, a number of MN designs including solid,
[15]
 coated,
[16]
 hollow,
[17]
 and most recently, 
dissolvable
[18]
 have been utilised to deliver DNA in preclinical studies. Of these, coated and 
dissolvable arrays provide the advantage of combining the vaccine cargo into the delivery 
device. A limitation of coated MN arrays is the relatively small dose that researchers can 
achieve without compromising needle conformation and hence penetration.
[19,20]
 As such 
dissolvable arrays may be more suitable for DNA vaccination as the cargo may be 
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incorporated throughout the entire matrix of the MN thereby increasing potential loading 
capacity.
[21,22]
 Dissolvable MN arrays further remove the inherent danger of needle buckling 
or breakage within the skin, minimise the risk of abuse or reuse, and provide a means to 
visually confirm dosage delivery.
[17] 
Previously, we reported on the design of a dissolvable Poly(Vinyl Pyrrolidine) (PVP) MN 
system incorporating pDNA cargo complexed to the cationic cell-penetrating peptide, RALA, 
to aid intra-cellular uptake.
[13,23]
 This device was capable of inducing robust humoural and 
cellular immune responses against the Human Papillomavirus (HPV) cervical cancer Tumour 
Associated Antigens (TAAs), E6 and E7.
[24]
 Furthermore, immunisation of mice utilising this 
dissolvable MN system decreased tumour uptake in both prophylactic and therapeutic tumour 
models.
[24]
 By thoroughly screening a range of dissolvable polymers for the MN fabrication 
process, this device has been further optimised to increase cargo transfection efficacies and 
payload.
[22]
 Despite these improvements, increasing the quantity of pDNA vaccine delivered 
from dissolvable MNs remains a considerable challenge. Therefore, the current study was 
designed to determine whether lyophilisation could be used to facilitate increased loading of 
the RALA/pDNA nanoparticle (NP) cargo within the dissolvable MN matrix, without 
compromising needle integrity or functionality. Firstly, a suitable lyophilisation process for 
NPs was identified. A novel MN formulation technique incorporating lyophilised NPs (L-
NPs) into a dissolvable 9-10 kDa PVA matrix was developed with in vitro and in vivo studies 
to demonstrate functionality. Finally, the superiority of the device compared to conventional 
i.m. injection was established in a therapeutic DNA vaccination study in a murine cervical 
cancer model. 
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2. Materials and Methods 
2.1 Formation of RALA/pDNA Nanoparticles (NP) 
The RALA peptide (WEARLARALARALARHLARALARALRACEA) was synthesised by 
Biomatik Corporation (USA), and reconstituted in DNase/RNase free water (Life 
Technologies, UK) for experimentation. Plasmids encoding green fluorescent protein (GFP), 
pEGFP-N1 (Clontech, USA), Firefly Luciferase, pLUX, and HPV-16 E6 and E7, pE6-E7 
(Addgene, USA), were transformed into competent Escherichia coli DH5α cells (Life 
Technologies, UK) and amplified prior to use as per the manufacturer’s instructions. 
Plasmids were isolated and purified using PureLink HiPure Plasmid Filter Maxiprep Kits 
(Life Technologies, UK), and reconstituted in DNase/RNase fee water. Plasmid purity and 
concentration was determined using a NanoDrop 2000c (Thermo Scientific, UK) according to 
UV absorbance at 260 nm and 280 nm. 
RALA/pDNA complexes were prepared by mixing pDNA with increasing amounts of RALA 
peptide at varying N:P ratios from 0-12 as previously described,
[23]
 and incubating for 30 min 
at room temperature (RT) to facilitate electrostatic interaction. 
2.2 Lyophilisation Protocol for NPs 
Unless otherwise stated, NP solutions were diluted 3:1 with 20% w/v trehalose (Sigma 
Aldrich, UK), to give a final concentration of 5% w/v trehalose. Solutions were transferred 
into a VirTis Wizard 2.0 (SP Scientific, USA) and subjected to freezing for 1 h at -40
o
C, 
before primary drying at -35
o
C for 3 h (120 mTorr), -30
o
C for 4 h (190 mTorr) and -25
o
C for 
4 h (190 mTorr). Finally, samples underwent secondary drying at 20
o
C for 18 h (190 mTorr 
for 8 h and 50 mTorr for 10 h). Lyophilised samples were stored at RT until required for 
experimentation. 
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2.3 Characterisation of Fresh NPs (F-NPs) and lyophilised NPs (L-NPs) 
50 µL samples of F-NPs or L-NPs (N:P 6) containing 1 µg of pDNA were loaded into 
polystyrene microcuvettes (Malvern Instrument Ltd, UK) and complex mean hydrodynamic 
size was determined by Dynamic Light Scattering using the Malvern Zetasizer NanoZS 
(Malvern Instrument Ltd, UK). Samples were diluted with 950 µL of DNase/RNase free 
water and transferred into a zeta-cuvette (Malvern Instrument Ltd, UK) for surface charge 
(zeta potential) determination using the Malvern Zetasizer NanoZS by Laser Doppler 
Velocimetry. 
F-NPs and L-NPs (N:P ratios 0-12) were prepared with 3 µg of pEGFP-N1 in a volume of  75 
μL. For gel retardation assays 10 µL of sample was supplemented with Nucleic Acid Loading 
Buffer (Bio-Rad, USA), loaded on to a 1% Agarose gel, and electrophoresed at 100 V for 1 h 
in 1X TAE buffer before visualising under UV light using a Multispectrum Bioimaging 
System (UVP, UK). To allow examination of pDNA tertiary structure, 10 μL samples were 
supplemented 1:1 with 1.0 mg/mL Proteinase K (Sigma, UK) and incubated for 120 min at 
37
o
C to allow degradation of the RALA peptide. Samples were then electrophoresed as 
above.  
To determine the NP encapsulation efficacy, 50 µL samples were diluted 1:2 with TAE 
buffer and placed in a black 96 well plate. Samples were incubated with 50 µL of diluted 
Quant-iT PicoGreen reagent (Life Technologies, UK) for 30 min at RT, excited by 
fluorescence at 480 nm and the fluorescent emission at 520 nm was measured using a 
Synergy 2 Multi-Mode Microplate Reader (BioTek Instruments Inc, UK). Percentage 
accessible pDNA was calculated relative to the fluorescence of pDNA only controls at 100%. 
2.4 In vitro assessment of NPs 
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In vitro assessment of F-NPs and L-NPs was performed in NCTC-929 cells, a murine 
fibroblast cell line which is recommended by ATCC for transfection and toxicity studies 
(https://www.lgcstandards-atcc.org/products/all/CCL-1). For cytotoxicity assays NCTC-929 
fibroblast cells (ATCC) were seeded into 96 well plates (10,000 cells/well), left to adhere 
overnight, and conditioned with Opti-MEM (Life Technologies, UK) for 2 h. Cells were 
supplemented with 50 µL/well of F-NPs or L-NPs (N:P 0-10) containing 1 µg of pDNA. 
Cells were incubated with complexes for 6 h at 37
o
C before being replaced in complete 
media. 24 h following transfection cells were supplemented with 10% CellTiter 96 Aqueous 
One Solution Reagent (MTS) (Promega, UK), and percentage toxicity was determined as 
previously described.
[22] 
For transfection studies NCTC-929 cells were seeded into 24 well plates (100,000 cells/well) 
and treated with NPs as above, with a total of 5 µg of pDNA/well. Cells were treated with F-
NPs, L-NPs or L-NPs which had been resuspended and dried in PVA. F-NPs or L-NPs (N:P 
6) were prepared with 5 μg of pDNA in a volume of 40 μL. PVA gels were prepared by 
resuspending L-NPs (N:P 6) containing 20 µg pDNA in 250 mg of aqueous 20% w/w 9-10 
kDa PVA stock solution. Once a homogenous solution had been formed, samples were 
transferred into non-indented silicon master-moulds using a spatula, and left to dry overnight. 
Gels containing RALA/pEGFP-N1 were subsequently stored at RT (21
o
C) for up to 28 days 
prior to use, while gels containing RALA/pE6-E7 were stored at 4
o
C, 21
o
C or 37
o
C for 28 
days. Gels were peeled carefully from the master-mould, and dissolved in 1000 µL of Opti-
MEM solution for 2 h at 37
 o
C, 250 µL of the solution was then used for transfection. 
GFP expression was visualised 48 h post transfection using an EVOS FL Cell Imaging 
System (Thermofisher Scientific, UK). Cells were harvested in 2% Formaldehyde, and GFP 
expression was quantified via flow cytometry using the FACS caliber system (BD 
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Biosciences, UK). Data was analysed using CellQuestPro software (BD Biosciences, UK). 
Fluorescent intensity is reported at 4% gating to untreated cells. 
For determination of expression of the HPV-16 E6 and E7 proteins, cells were harvested in 
radio immune precipitation assay (RIPA) buffer 48 h following transfection. Samples (20 μg) 
were electrophoresed through a 4-12% sodium dodecyl (SDS)-polyacrylamide gel (Life 
Technologies, UK), transferred onto a nitrocellulose membrane (Hybond-C, Amersham; UK) 
and probed with HPV-16 E6 and HVP-16 E7 antibodies (Abcam; UK). GAPDH was used as 
a loading control (Sigma; UK). Levels of protein expression were assessed using an 
Immobilon western detection kit (Millipore; UK). X-ray films were scanned using benchtop 
UV transilluminators (UVP Products Ltd) and density was calculated using Image J 
(http://rsbweb.nih.gov/ij/) incorporating correction of loading controls. 
2.5 Microneedle (MN) Fabrication 
For fabrication of MNs, L-NPs (N:P 6) were prepared using 100 µg of pDNA. 30 mg of 20% 
w/w 9-10 kDa PVA solution was used to reconstitute the lyophilisate and once a homogenous 
mixture had been formed, the PVA-NP solution was transferred into a silicon mould 
containing 19x19 inverted conical projections with dimensions of 300 µm diameter and 600 
µm length, spaced 50 µm apart, which has been described elsewhere.
[25]
 PVA-NP was 
centrifuged for 5 min at 4,000 rpm to fill the projections. Following centrifugation 500 mg of 
inert 20% w/w 9-10 kDa PVA solution was added above the filled projections and re-
centrifuged to form an empty baseplate. Needles were left to dry for 48 h at RT before 
removal from the mould (Figure 2C).  
2.6 Visual assessment and mechanical testing of MN needle arrays 
The sidewalls of MN arrays were removed with scissors. Arrays were subsequently adhered 
to a flat metal block using double-sided sticky tape, faced perpendicularly to the lens of a 
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Leica EZ4D digital microscope (Leica, Germany) and imaged at x35. For compression 
studies, MNs were stored at RT for up to 28 days prior to analysis. Needles were pressed 
against a flat aluminium block using the movable probe of the TA-XT2 Texture Analyser 
(Stable Microsystems, UK), with a force of 45 N (0.125 N/needle), for 30 s. Following 
compression, the needles were re-imaged using the Leica EZ4D digital microscope. The 
percentage needle height reduction was subsequently determined as previously described.
[22] 
2.7 Assessment of MN penetration into neonatal porcine skin via Optical Coherence 
Tomography (OCT) 
Full thickness neonatal porcine skin was harvested from stillborn piglets and stored at -20
o
C 
between experiments. Prior to analysis, skin was thawed in PBS at 37
o
C for 30 min and hair 
was carefully removed using a disposable razor. Skin was placed onto a sheet of dental wax 
for support, with the SC side facing up, and cleaned with a 70% Ethanol wipe prior to MN 
insertion. A piece of sticky tape was placed over the flat side of the baseplate of MNs loaded 
with NP (NP-MN) or pDNA (DNA-MN), and MNs were subsequently placed onto the SC 
surface, inserted into the skin using manual thumb pressure, and held in place for 30 s. 2D 
images of needle penetration were obtained using an EX1301 OCT microscope (Michelson 
Diagnostics Ltd, UK) and Image J software (National Institutes of Health, USA) was used to 
analyse images of penetration as previously described.
[22] 
2.8 Quantification of pDNA encapsulation within the microneedle array 
The quantity of pDNA residing in the MN was determined using the PicoGreen assay as 
described previously.
[13,22]
 Briefly, the sidewalls, and the arrays (baseplate and needles) were 
dissolved in 10 mM TRIS buffer (pH 8), incubated with 1.0 mg/mL Proteinase K for 2 h at 
37
o
C, and 50 µL samples were supplemented with Quanti-iT PicoGreen reagent. The quantity 
of released pDNA was determined using a standard curve. 
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2.9 Application of NP-laden dissolvable microneedles in vivo 
All animal experiments complied with the UK Scientific Act and were carried out under 
Project License 2794. For all experiments MNs were applied to the dorsal side of the ears of 
female C57 BL/6 mice (6-8 weeks old). Application was as previously described,
[22]
 where 
unless stated otherwise MNs were held into the skin for 5 min prior to being adhered in place 
for a further 24 h with 3M Surgical tape (Micropore Ltd, UK). After this time arrays were 
removed by wetting the tape and gently peeling. 
2.10 Quantification of NP delivery from dissolvable microneedles in vivo 
To provide an estimate of delivery from MNs, NP-MNs were applied to the ears of mice for 
either 5 min with pressure or for 5 min with manual pressure followed by taping arrays in 
place for 24 h. Following removal, the quantity of pDNA remaining in the MN was 
determined using the PicoGreen assay. pDNA delivery was estimated by subtracting the 
quantity of pDNA remaining in MN following application from the quantity of pDNA in 
unapplied MNs. 
2.11 Quantification of Luciferase expression using quantitative real-time polymerase 
chain reaction (qRT-PCR) 
Mice were treated with MNs manufactured with 32 μg of non-lyophilised pLUX (N:P 6), 
prepared as previously described,
[22]
 or with MNs manufactured with 100 μg of L-pLUX 
(N:P 6). 48 h following application, the whole ear was harvested and placed TriZol® 
(Thermofisher Scientific, UK) reagent for mRNA extraction. Tissues were homogenised by 
oscillating in a TissueLyser LT (Qiagen, UK) at 50 osc/sec for 10 min and subsequently 
following the manufacturer’s instructions. RNA purity and concentration were determined 
according to UV absorbance at 260 nm and 280 nm. mRNA was treated to remove 
contaminating DNA using a DNase I, RNase-free kit (Thermofischer Scientfic, UK) as per 
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the manufacturer’s instructions. To allow conversion of mRNA to cDNA, 1 µg of mRNA 
was added to 10 µL of Reverse Transcription mix (4 µL 5X First Strand Buffer, 1 µL 10 mM 
dNTP mix, 1 µL Dilute Random Primer, 2 µL 0.1 M DTT, 1 µL RNase OUT 40U/mL, 1 µL 
M-MLV Reverse Transcriptase, [ Invitrogen, UK]). Samples were heated to 25
o
C for 5 min, 
37
o
C for 90 min, and 70
o
C for 10 min, before being cooled to 4
o
C. Following reverse 
transcription, 1 µL of cDNA sample was transferred to a qRT-PCR 96 well plate (Roche, 
UK). 9 µL of Mastermix (5 µL SYBR Green [Roche, UK], 3 µL DNase/RNase free water, 1 
µL primer) was added to each sample. Primers were designed using the NCBI Primer Blast 
program and fabricated by Integrated DNA Technologies (UK), the Luciferase forward and 
reverse primer sequences were 5’-TCGTGACTTCCCATTTGCCA-3’ and 5’-
GGGATGATCTGGTTGCCGAA-3’ respectively, β-actin forward and reverse primer 
sequences were 5’-AGA AAA TCT GGC ACC ACA CC-3’ and 5’-TAG CAC AGC CTG 
GAT AGC AA-3’ respectively. Plates were placed in to a Lightcycler 480 II (Roche, UK) 
and incubated at 95
o
C for 5 min, before amplification for 45 cycles at 95
o
C for 10 s, 60
o
C for 
10 s and 72
o
C for 10 s. Ct values were generated by the machine’s software, and were used to 
quantify the expression of Luciferase relative to the β-actin housekeeper gene, Luciferase 
expression is reported relative to untreated control. 
2.12 Quantification of luciferase expression in vivo via bioluminescence imaging 
MNs containing lyophilised pDNA (DNA-MN) or NPs (NP-MN) were applied to mice. 24 h 
following MN removal, mice were injected i.p. with 200 µL of D-Luciferin (15 mg/mL) and 
luminescence was detected 10 min later via whole body imaging using the In-Vivo Xtreme 
Imaging System (Bruker, UK). Emission images were captured for 5 min and the 
luminescence of individual ears was determined using LivingImage 3.2 software (Leica, UK). 
Mice were then sacrificed via schedule 1 killing, and the organs were harvested, transferred 
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to a 6 well plate, and bathed in 15 mg/mL D-Luciferin for a further 10 min prior to imaging 
as above. 
2.13 Immunisation of mice  
Mice were divided into treatment groups and immunized with 100 μg of pE6-E7.  The 
treatment groups were as follows: untreated control, naked pDNA via i.m. injection (DNA-
IM), naked pDNA via MN (DNA-MN), NP via i.m. injection (NP-IM) and NP via MN (NP-
MN). For MN treatment, one MN was applied to each ear. Vaccination was followed by a 2
nd
 
and 3
rd
 booster immunisation every 2 weeks.  
2.14 ELISA for detecting anti-E6/E7 antibodies 
An indirect ELISA was carried out one week after the 2
nd
 and 3
rd
 boosts to determine E6/E7 
specific IgG antibodies in mice sera. A Nunc MaxiSorp 96 well plate (ThermoFisher 
Scientific, UK) was coated with 100 µl of purified HPV-16 E7/E6 peptides (ProImmune, 
UK) at 0.5 mg/ml and incubated at 4°C overnight. After washing with PBS containing 0.05% 
Tween 20, the wells were then blocked with PBS containing 20% fetal bovine serum and 
incubated at 4°C for 16 h. Serum samples diluted in PBS (1:100) were added to the ELISA 
wells, and incubated at 37°C for 2 h. After washing with PBS/Tween 20, the plate was 
incubated with a 1:2000 dilution of a goat anti-mouse IgG HRP-conjugated antibody (Sigma, 
UK) at RT for 1 h. After a final wash, an enzyme substrate (OPD, Sigma) was added for 
colour development. Immuno-reactivity was detected with an ELISA plate reader at 450 nm. 
Quantification of IgG was performed using an Easy Titer IgG assay kit (Thermo scientific, 
UK) with a standard curve. 
2.15 Cytotoxicity and Interferon(IFN)- γ assay 
One week following the 3
rd
 immunization, the spleen from each mouse was removed, 
homogenized and re-suspended in Red Blood Cell (RBC) lysis buffer (Sigma, UK) to remove 
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RBCs. T cells (effecter cells) were co-cultured at a ratio of 10:1 with irradiated TC-1 cells 
(10
4
 per well) (target cells) in RPMI-1640 medium with 20 units of interleukin-2 (Peprotech, 
UK) in 24-well plates at 37°C. Dead T cells were removed by centrifugation with Percoll 
solution (Amersham Biosciences) for up to 6 days. Following 4 days of stimulation, the 
supernatant of each sample was taken and debris was removed by centrifugation. IFN- γ was 
detected using an IFN-γ ELISA kit (Peprotech, UK) as per the manufacturer’s instructions. 
Following 6 days stimulation viable T cells were seeded with non-irradiated TC-1 cells at a 
ratio of 10:1 in 1% BSA medium, at 37°C for 5 h in 96-well plates. After 5 h, the supernatant 
of each sample was collected and TC-1 cytotoxicity was measured using a LDH cytotoxicity 
detection kit as per the manufacturer’s instructions (Roche, UK).   
2.16 Tumour therapeutic assay 
Female C57BL/6 mice were challenged i.d. on the rear dorsum with 1X10
5
 TC-1 cells. When 
tumours reached 50 mm
3
, mice were immunized three times as stated in section 2.13, but at 
weekly intervals. Mice were monitored for evidence of tumour growth by palpation and 
measurement with callipers three times a week. All mice were culled one week following the 
3
rd
 immunization and tumour weights were analysed. 
2.17 Statistical Analysis 
Unless otherwise stated, all experiments had three independent repeats. Results are expressed 
as the mean ± standard deviation (SD). Statistical differences between groups were 
determined using a two-tailed, unpaired t test, or a One-Way ANOVA, with a P value ≤ 0.05 
considered significant. For all analyses, data sets were assumed to be normal and possess 
homogeneity of variance. 
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3. Results 
3.1 Characterisation of F-NP and L-NPs 
 
Figure 1. Characterisation of Fresh Nanoparticles (F-NPs) and Lyophilised NPs (L-NPs). (A) F-
NP and L-NP size and zeta potential (N:P 6). Asterisk denotes a significant difference (Student’s t-
test, * p < 0.05). (B) Cytotoxicity of NPs over a range of N:P ratios (0-10) in the NCTC-929 cell line  
by MTS; (C) Encapsulation Efficiency of NPs over a range of N:P ratios (0-12); (D) Gel retardation 
assay of (i) F-NPs and (ii) L-NPs at various N:P ratios (0-12). i) Lane 1: DNA Ladder; Lanes 2-9: F-
NPs prepared at N:P ratios 1-12, ii) Lane 1: DNA Ladder; Lane 2: pDNA only; Lane 3: pDNA + 5% 
trehalose (T); Lanes 4-11: L-NPs prepared at N:P ratios 1-12. (E) DNA integrity study of (i) F-NPs 
and (ii) L-NPs at various N:P ratios (0-12). Lane map as per (D). Decomplexation with of NPs with 
proteinase K. Graphs represent mean + SD (N=3 for all studies). 
F-NPs had a mean hydrodynamic size of 37.96 nm and a zeta potential of 17.92 mV. 
Following lyophilisation, NP mean hydrodynamic size increased significantly to 74.93 nm (p 
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< 0.05) (Figure 1-A), however the zeta potential of L-NPs showed no significant difference to 
F-NPs (11.77 mV, p > 0.05). The affect of N:P ratio and lyophilisation on cell viability was 
next assessed in the NCTC-929 cell line by MTS assay 24 h following transfection (Figure 1-
B). Transfection with F-NPs or L-NPs did not result in a significant decrease in cell viability 
compared to control, and no drop in viability below 80% of untreated controls was observed 
across the range of transfection conditions (Figure 1-B). The encapsulation efficiency of F-
NPs and L-NPs was  determined via the PicoGreen assay, which has been utilised previously 
to determine changes in NP structure following lyophilisation.
[26]
 Consistent with previously 
reported data,
[23]
 as the N:P ratio of  F-NPs increased, the percentage of accessible pDNA 
within solutions decreased, from 100% at N:P 0, to 79.2% at N:P 1, and at N:P ratios ≥ 2 
approximately 20% of pDNA was accessible to PicoGreen, due to pDNA being complexed to 
RALA. The percentage of pDNA accessible to PicoGreen within L-NPs was similar to that of 
F-NPs with 72.4% of pDNA binding PicoGreen at N:P 1, and at higher N:P ratios 
approximately 20% of pDNA from L-NPs was able to bind PicoGreen (Figure 1-C). The gel 
retardation assay was next used to determine the ability of the RALA peptide to neutralise the 
charge of negatively charged pDNA. RALA neutralised the charge of pEGFP-N1 from an 
N:P ratio of 2 onwards (Figure 1-Di) as shown by the inability of the pDNA to migrate 
through the gel. L-NPs followed a similar condensation pattern, where beyond N:P 2 pDNA 
was retained within gel wells, indicating that NPs remained intact following lyophilisation 
(Figure 1-Dii). 
Lastly, prior to incorporation into the dissolvable PVA matrix, the affect of lyophilisation on 
pDNA tertiary structure was determined using gel electrophoresis, an established and 
powerful technique to separate pDNA conformations due to their differing migration rates 
within an agarose gel
27–29
 (Figure 1-E). To allow migration of pDNA through the agarose gel 
under current, NPs were incubated with Proteinase K to degrade the RALA peptide prior to 
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analysis. Control pDNA can be seen to reside predominantly in the supercoiled, as well as 
linear and nicked conformations (Figure 1-Ei, Lane 2). Following complexation with RALA 
(N:P 0-12) and incubation with Proteinase K, pDNA remained in the same conformations as 
prior to complexation, indicating no damage to pDNA during NP formation (Figure 1-Ei, 
Lanes 3-10). Following lyophilisation (Figure 1-Eii, Lanes 4-11), there was a loss of the 
pDNA supercoiled conformation, and increase in the linear and nicked conformations 
indicating pDNA damage during lyophilisation. 
3.2 NP functionality is not compromised following lyophilisation or incorporation into 
the dissolvable microneedle matrix 
To determine whether NPs retained functionality following lyophilisation, NCTC-929 cells 
were used as a model cell line for transfection studies (Figure 2-A and -B). Consistent with 
previously reported data, F- NPs (N:P 6) transfected 61.4% ± 0.4 of cells.
[23]
 L-NPs with no 
protectant lost approximately 2/3 transfection efficacy compared to F-NPs (19.0% ± 3.1) 
indicating damage during the freeze-drying process. Conversely, addition of 5% w/v 
trehalose prior to lyophilisation was sufficient to conserve ~95% of NP transfection efficacy 
(58.1% ± 4.5). To determine the impact of incorporation into the 9-10 kDa PVA matrix, L-
NPs were directly reconstituted into 9-10 kDa PVA stock solution and dried for 24 h at RT 
prior to transfection studies. Following dissolution from the dehydrated polymer gels, NP 
transfection efficacy decreased to 47.7% ± 14.7, although this was not significantly lower 
than the transfection efficacies of F-NPs or L-NPs (p > 0.05), therefore incorporation into 9-
10 kDa PVA was not considered detrimental to the formulation process. 
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Figure 2. Effect of manufacturing process on NP functionality and release from dissolvable 
microneedle (MN) array. (A) Typical fluorescent microscope images of GFP transfection within the 
NCTC-929 cell line following transfection with: i) F-NPs, ii) L-NPs without trehalose (T), iii) L-NPs 
and iv) L-NPs reconstituted and dried within aqueous PVA (L-NP + PVA); (B) Flow cytometric 
analysis of GFP expression in the NCTC-929 cell line 48 h post-transfection with NPs treated as 
above. Asterisk denotes a significant difference (One-Way ANOVA, * p < 0.05). (C) Schematic 
representation of dissolvable MN fabrication process; (D) Quantification of pDNA recovery from 
PVA MNs loaded with L-NPs. Graphs represent mean + SD (N=3 for all studies). 
3.3 Manufacture of and pDNA recovery from dissolvable MN array 
Dissolvable 9-10 kDa PVA arrays were fabricated using 100 μg of lyophilised pDNA 
complexed to RALA (N:P 6) (Figure 2-C) (NP-MN). The quantity of pDNA recovered from 
the microneedle array (baseplate and microneedles) was determined separately from that in 
the sidewalls, to allow quantification of the pDNA lost during manufacture, and that available 
for delivery (Figure 2-D). The quantity of pDNA released from within the array was 57.29 
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μg. The quantity of pDNA released from the discarded side walls was 17.04 μg. Hence, the 
total quantity of pDNA recovered from MNs formulated using the novel manufacturing 
method was 74.33 μg, indicating that 25.67 μg of pDNA is lost during manufacture. Details 
of NP transfection efficacy and loading within MN patches following processing and 
manufacture are suimmarised in Table 1. 
Table 1. Transfection Efficacies and loading of NPs within 9-10 kDa PVA microneedle 
(MN) arrays following various formulation techniques. The transfection efficacy of NPs 
following a number of processing steps was established in the NCTC-929 cell line. NPs 
processing was as follows: Fresh NPs (F-NPs); NPs lyophilised with (L-NP) and without 
Trehalose (L-NP – T); F-NPs incorporated into 9-10 kDa PVA MN matrix (F-NP + PVA); L-
NP incorporated into 9-10 kDa PVA MN matrix  (L-NP + PVA). The loading of NPs within 
PVA MN patches formulated using the previously reported
22
 (Method 1) and novel (Method 
2) manufacturing processes were determined using the Picogreen Assay. 
 
3.4 L-NP loaded MN arrays (NP-MN) are functional and mechanically robust 
  
19 
 
 
Figure 3. In vitro characterisation of L-NP loaded MNs (NP-MN). (A) Light microscope images of 
NP-MNs i) prior to and ii) following compression with a 45 N axial load; (B) Percentage Height 
Reduction of NP-MNs and (C) Transfection efficacy of L-NP following dissolution from PVA MNs, 
following incubation at RT over a 28 day period; (D) Optical Coherence Tomography (OCT) Images 
of i) PVA MNs loaded with lyophilised DNA (DNA-MN) and ii) NP-MNs; (E) Quantification of 
percentage penetration through the stratum corneum of DNA-MNs and NP-MNs. Graphs represent 
mean + SD (N=3 for all studies). 
NP-MN were dried at RT for 24 h prior to peeling from the master-mould and imaging prior 
to (Figure 3-Ai), and following (Figure 3-Aii), compression with an axial force of 45 N. NP-
MNs formed sharp, conical micro-projections approaching ~600 μm in length. Following 
compression, the tips of arrays showed a blunting, and underwent a height reduction of 6.74 ± 
1.8% although no major mechanical failure/breakage was observed in any of the tested 
arrays. The short term mechanical and functional stability of NP-MNs was assessed over a 28 
day period via axial load compression and flow cytometry. Following 7, 14 and 28 days 
incubation at RT the percentage height reduction of NP-MNs was 5.26%, 6.00% and 5.93% 
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respectively following compression, which was not significantly different than that following 
0 days incubation (Figure 3-B, p > 0.05), indicating that NP-MNs did not lose strength over 
the 28 day incubation period. Following 7, 14 and 28 days incubation at RT the transfection 
efficacy of L-NPs (recovered from 9-10 kDa PVA gels) was 44.2%, 42.3% and 42.0% 
respectively (Figure 3-C). These transfection efficacies were not significantly lower than that 
achieved by F-NPs (47.8%, p > 0.05), indicating that the transfection efficacy was not 
compromised by short term storage. 
To determine whether NP-MNs effectively penetrated the SC, NP-MNs were pressed 
manually into shaven neonatal porcine skin for 30 s, and imaged using OCT (Figure 3-D). 
Images revealed that penetration across the SC was deep and consistent with both pDNA-
loaded (DNA-MNs) (Figure 3-Di) and NP-MNs (Figure 3-Dii). DNA-MNs and NP-MNs 
achieved penetration depths of 73.0% and 74.5% respectively, which was not significantly 
different than the penetrations achieved with empty 9-10 kDa PVA arrays previously 
observed (Figure 3-E, p > 0.05).
[22]
 
 
 
 
 
 
3.5 NP-MNs deliver large quantities of cargo and are capable of eliciting reporter gene 
expression in vivo 
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Figure 4: In vivo characterisation of NP-MNs. (A) Quantification of pDNA (i) remaining in and (ii) 
delivered from NP-MNs following 5 min or 24 h application to mouse ears. Graphs represent mean + 
SD, N = 3, asterisk denotes a significant difference (student’s t-test, * p < 0.05). (B) Quantification of 
luciferase mRNA levels in the ear tissue  relative to β-actin, reported as fold change relative to 
untreated control. Graph represents mean + SD, (N = 3/4); (C) Representative images of gene 
expression captured via the IVIS imaging system from the i) dorsal side and ii) harvested organs of 
mice 48 h following application of DNA-MN or NP-MN encoding luciferase to the dorsal side of 
ears; (D) Quantification of gene expression from the i) ears, ii) liver, and iii) kidneys of mice 48 h 
following DNA-MN or NP-MN application. Graphs represent mean + SD, N = 3. Asterisk denotes a 
significant difference (One-Way ANOVA, * p < 0.05). 
To estimate the quantity of pDNA which could be delivered from arrays in vivo, NP-MNs 
were applied to the dorsal side of mouse ears. Following 5 min of application, 33.41 μg of 
pDNA remained in MNs, which was significantly higher than the 4.40 μg of pDNA 
remaining in MNs following 24 h application time (Figure 4-Ai, (p < 0.05). Hence the 
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quantity of pDNA delivered following application of NP-MNs for 5 min or 24 h was 
estimated to be 23.88 μg and 52.89 μg respectively (Figure 4-Aii, p < 0.05). 
The ability of pLUX and RALA/pLUX-loaded MNs to elicit gene expression in vivo was 
next determined using qRT-PCR and whole body luminescence imaging. Following 
application of arrays manufactured with 32 μg of non-lyophilised pLUX, prepared as 
previously described,
[22]
 there was no detectable increase in luciferase expression in the ear 
tissue compared to untreated control (1.343-fold). However, luciferase expression was 
increased 4.114-fold following application of arrays manufactured with 100 μg of L-NPs 
(Figure 4-B). 
Following this, mice were treated with DNA-MNs or NP-MNs and 48 h following 
application, luciferase protein expression was analysed using the IVIS imaging system 
(Figure 4-C). Imaging revealed a significant increase (p < 0.05) in luminescence within ears 
which had been treated with NP-MNs, compared to control (untreated ears), indicating 
successful local transfection (Figure 4-Di). Application of DNA-MNs resulted in a small 
increase in luminescence compared to untreated ears, although this was not significant (p > 
0.05). To determine whether delivery of cargo into the ear resulted in gene expression beyond 
the application site, mice were sacrificed and the main organs were imaged. Analysis 
revealed no significant increase in the luminescence of livers from MN treated mice 
compared to control (Figure 4-Dii, p > 0.05,). Conversely, kidneys from mice treated with 
NP-MNs demonstrated significantly increased luminescence compared to untreated mice, 
(Figure 4-Diii, p < 0.05), indicating gene expression within the kidney. Although application 
of DNA-MNs did result in a small increase in luminescence within the kidney, this was not 
significant (p > 0.05). 
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3.6 RALA/pE6-E7 NPs are functional following lyophilisation and incorporation into 
the PVA matrix 
Expression of the HPV-16 E6 and E7 proteins following transfection of NCTC-929 cells with 
F-NPs or L-NPs was confirmed via western blot (Figure 5-A). Expression of each of the 
proteins was apparent following transfection with NPs, but not with DNA alone, highlighting 
that RALA is necessary to facilitate transfection. Further to this it was demonstrated that L-
NPs remained functional following incubation in the polymer matrix over a range of 
temperatures (4
o
C, 21
o
C and 37
o
C), for up to 28 days (Figure 5-B). 
 
Figure 5: Functionality of pE6-E7 NPs following formulation and storage within NP-MNs. (A) 
Western Blot analysis of HPV16 E6 and E7 expression 48 h following transfection of NCTC-929 
cells with fresh or lyophilised pE6-E7 DNA and NPs (B) Western Blot analysis of HPV16 E6 and E7 
expression 48 h following transfection of NCTC-929 cells with L-DNA and L-NPs released from the 
PVA MN matrix following storage at 4
o
C, 21
o
C or 37
o
C for 28 days. 
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3.7 Immunisation of mice via MN is able to generate a potent humoural and cellular 
immune response against the encoded HPV16 E6 and E7 antigens 
Following two or three immunisations, raised serum anti-E6/E7 IgG levels were present in all 
experimental groups compared to control mice, with the exception of mice treated with empty 
MNs (Figure 6-A). Mice immunised with NP-MN showed the highest levels of antigen-
specific IgG (80.06 µg/mL and 61.64 µg/mL after 2 or 3 immunisations respectively), which 
were significantly higher than those of naïve mice at the same time points (24.68 µg/mL and 
25.56 µg/mL, p < 0.05). 
The cytolytic activity of splenic T cells, from immunised and untreated mice, against TC-1 
tumour cells was assessed using the LDH release assay (Figure 6-B). The highest level of 
TC-1 cell lysis was observed in mice immunised with NP-MN, which was double that 
observed in untreated controls (43.3% vs 21.4%, p > 0.05). An increased TC-1 specific cell 
lysis was also observed in mice immunised with NP-IM (37.38%), DNA-IM (33.58%) or 
DNA-MN (30.89%). 
Lastly, the ability of RALA encapsulated pE6-E7 to evoke a specific cytolytic T cell response 
was tested in established TC-1 tumours (Figure 6-D). Mice treated with NP-IM showed a 
considerable decrease in final tumour mass compared to untreated control mice (0.997 g and 
2.29 g respectively, p > 0.05). However, this decrease was markedly enhanced by treating 
with NP-MN (0.629 g, p < 0.05,). Conversely, treatment with DNA-IM or DNA-MN did not 
result in a decrease in tumour mass (1.695 g and 2.170 g respectively) indicating that 
complexation with the RALA peptide was necessary to induce a therapeutic response in vivo. 
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Figure 6: Evaluation of NP-MN mediated immune response to E6-E7
+
 TC-1 cervical cancer cells 
in vivo. Mice were treated with empty MN (MN), DNA-IM, DNA-MN, NP-IM and NP-MN three 
times at two weekly intervals. Following sacrifice splenic T cells were harvested, purified and 
stimulated in vitro with irradiated TC-1 cells. (A) Evaluation of serum antigen-specific IgG titres one 
week following the second and third immunisations. Graph represents mean + SD, (N = 3/4). Asterisk 
denotes a significant difference (One-Way ANOVA, * p < 0.05).; (B) Determination of T cell-
mediated toxicity of healthy TC-1 cells, following 6 days co-culture with irradiated TC-1 cells; (C) 
Determination of IFN-γ secretion from isolated T cells following 4 days co-culture with irradiated 
TC-1 cells. Graphs B and C represent mean + SD, (N = 3/4). Asterisk denotes a significant difference 
(One-Way ANOVA, * p < 0.05). (D) Mice were challenged with 1 x 10
5
 TC-1 cells i.d. on the rear 
dorsum. When tumours reached 50 mm
3
 mice received three immunisations as above at weekly 
intervals. One week following the final immunisation tumours were harvested and weighed. Graph 
represents mean + SD, N = 3. Asterisk denotes a significant difference (One-Way ANOVA, * p < 
0.05). 
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4. Discussion 
Previously we reported on the fabrication of a novel two-tiered delivery system comprised of 
a dissolvable polymer MN matrix, encapsulating cationic RALA/pDNA NPs.
[13,22]
 During the 
manufacturing process the loading capacity of the device was limited by the volume of 
solution which could be diluted into the dissolvable matrix without compromising the 
physical integrity of the dried formulation.
[22]
 This is a common limitation of coated and 
dissolvable MN formulations where the payload is frequently <10 µg.
[18,19,30]
 Attempts to 
increase the concentration of pDNA solutions prior to incorporation into the MN matrix are 
constrained by the inherent viscosity of pDNA, and the instability of over-concentrated 
cationic NPs in solution.
[19,31,32]
 Increasing this restricted payload would be a significant 
advancement for MN-based DNA vaccines for two reasons: Firstly, delivery of a higher 
quantity of pDNA is likely to result in higher levels of antigen expression. Secondly, pDNA 
vaccines possess inherent adjuvant activity due to the presence of CpG motifs in the plasmid 
backbone, which promote DC activation through toll-like receptor 9 (TLR9) stimulation, as 
such, delivery of greater quantities of pDNA will result in greater DC maturation, migration 
and T cell priming. This prompted us to develop a novel manufacturing process using 
lyophilisation to increase MN loading capacity. By removing water from the cargo solution 
and directly reconstituting the lyophilised cake into a smaller volume of aqueous MN matrix 
we hypothesised we could significantly increase the device payload compared to our 
previously described formulations.
[22]
 This process has been explored previously to 
concentrate inactivated influenza vaccine (A/PR/8/34),
[33]
 and Human Papilloma Virus 
Pseudoviruses (HPV-PsV), within dissolvable and coated MNs,
[34]
 however, no studies have 
utilised lyophilisation to concentrate pDNA or pDNA-based cationic NPs within dissolvable 
MNs.  
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 However, lyophilisation can be detrimental to NP size, zeta potential and encapsulation 
efficiency, due to the stresses placed on particles during freezing and drying.
[32,35–37]
 
Trehalose has demonstrated the ability to conserve the functionality of NPs during 
lyophilisation without the need for other excipients,
[38,39]
 and therefore was selected for initial 
studies examining the physical integrity of the L-NPs. The addition of 5% w/v trehalose 
during lyophilisation was unable to fully conserve NP size, however complex sizes were 
maintained < 150 nm, which is essential for efficient endocytosis .
[40]
. L-NPs also maintained 
a cationic zeta potential and encapsulated pDNA in a manner similar to F-NPs, indicating that 
the electrostatic interactions between the cationic RALA peptide and anionic pDNA are 
sufficiently strong to prevent any pDNA dissociation during lyophilisation. 
Examination of pDNA integrity within L-NPs revealed a notable loss of the supercoiled 
conformation, especially where pDNA was complexed to a lower concentration of RALA. 
This is due to the decreased zeta potential at low N:P ratios, which leads to greater 
aggregation, and pDNA damage, due to reduced charge repulsion.
[23]
 Interestingly, Mohajel 
et al (2012) noted that despite lyophilisation of chitosan/pDNA complexes resulting in a loss 
of the supercoiled portion of pDNA, which is considered the most important conformation for 
achieving high transfection efficacies,
[41]
 this did not affect the transfection efficacy of the 
polyplexes.
[42]
 Similarly, we found that L-NPs retained ~95% transfection efficacy. 
Assessment of cell viability following transfection with F-NPs and L-NPs confirmed that 
complexes were not toxic, and it was concluded that the L-NPs were suitable for 
incorporation into dissolvable MNs.  
Previous studies have indicated the need to determine the cargo functionality following both 
lyophilisation and incorporation into the MN formulation, due to the stresses of a secondary 
drying step within the polymer matrix, which may result in aggregation.
[33]
  Indeed, L-NPs 
demonstrated an approximate 25% decrease in transfection efficacy following incorporation 
  
28 
 
into PVA (61.4% vs 47.7%), and therefore in future studies, optimising the drying process or 
including additional protectants within the aqueous MN matrix may be beneficial to conserve 
activity during MN formulation.
[20,43,44]
 However, we did not investigate these strategies in 
the present study, as NPs retained a high transfection rate (~75% compared to F-NPs). 
We next demonstrated that this novel fabrication process could be used to increase the pDNA 
MN loading compared to our previously reported cumbersome fabrication process.
[22]
 
Formulated MNs resembled those manufactured previously, with sharp uniform tips, and 
heights approximate to the shape of the mastermould. NP-MNs resisted major deformation or 
fracture under compression forces necessary for manual application,
[45]
 and penetrated 
neonatal porcine skin in a similar manner to unloaded arrays. This novel fabrication process 
allowed an approximate seven fold concentration of the NP cargo, and permitted a loading of 
57 μg of pDNA per MN (in addition to 496 μg of RALA peptide), which is significantly 
higher than the loadings achieved by other authors. For example, Gonzalez-Gonzalez et al 
(2010) succeeded in loading their PVA-based micron-scale Protrusion Array Device (PAD) 
with 144 ng of pDNA,
18
 while Liao et al (2017) achieved greater loadings of  ~ 20 µg of 
pDNA per device in PVA/PVP microneedles.
29
 
 In vivo application of MNs allowed deposition of ~50 μg of pDNA per patch, which is a 
significant improvement over the quantities of pDNA which have previously been delivered 
from similar dissolvable MNs.
[13,18]
 qRT-PCR confirmed that increasing the payload resulted 
in higher levels of local luciferase mRNA expression compared to our previously described 
MN patch which was able to deliver ~12 μg of pDNA.[22,24] Further to this it was established 
that arrays were capable of eliciting protein expression in vivo, as this is a prerequisite to the 
induction of an immune response. Our previously described MN system was only able to 
produce detectable levels of gene expression within the highly vascularised liver and kidneys, 
indicating systemic uptake, and accumulation within these organs.
[13,23]
 While the expression 
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of immunogenic protein(s) within organs other than the skin is not expected to result in any 
off-target toxicity, the epidermis and dermis are the primary targets for vaccination owing to 
their wealth of APCs. Therefore this novel formulation is more ideal for DNA vaccination 
purposes, as treatment generated local gene expression within the ear, as well as the kidneys, 
of mice.  
One of the reported major advantages of dissolvable MNs has been the supposition that cargo 
stored within the dry state may be more stable than liquid vaccines which require 
refrigeration. Two parameters which commonly affect the usability of dissolvable MNs over 
storage include a loss of strength or shape due to imbibing environmental water,
[46]
 and 
secondly, loss of cargo functionality.
[43,44]
 However, over a 28 day period no significant 
change in MN strength or cargo functionality were noted, indicating that MNs should retain 
sufficient strength to penetrate the SC and  may protect cargo without the need for cold chain 
storage.  
Finally, we tested the efficacy of this novel NP-MN system in a preclinical cervical cancer 
model. NP-MN evoked the greatest antigen-specific humoural response in immunized mice, 
with the E6 and E7 specific IgG titers being approximately 1.7 fold higher than those elicited 
by NP-IM. This supports that delivery to the APC-rich layers of the dermis and epidermis 
enhance DNA vaccine immunogenicity. Furthermore, antibody titres induced by NP-MN 
were 1.6 fold higher than those elicited DNA-MN, demonstrating that RALA significantly 
improves cellular uptake, and hence activation of an immune response. To be effective 
against established infections or tumours, DNA vaccines must also be capable of generating 
antigen-specific CTLs which are capable of directly lysing infected or cancerous cells.
8
 
Immunisation of mice with NP-MN resulted in the largest increase in TC-1 specific 
cytotoxicity via isolated CD8+ T cells, which was two-fold higher than that of unimmunised 
mice. Furthermore, antigen-specific IFN-γ secretion was significantly raised only from T 
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cells isolated from animals immunised with NP-MN, highlighting the superiority of this DNA 
vaccination system. Most importantly, we demonstrated the ability of NP-MNs to retard the 
growth of established TC -1 tumours in vivo. NP-MN treatment proved the most effective in 
reducing tumour burden and significantly reduced (3.6 fold) tumour weight compared to 
control mice, demonstrating that this system is able to generate a potent therapeutic 
antitumour effect. In agreement with others we found that naked pDNA was poorly 
immunogenic, and that i.d. immunisation significantly increased vaccine potency.
[11,15,19] 
In conclusion, by utilising lyophilisation to concentrate pDNA cargo we have successfully 
overcome one of the main limitations of coated and dissolvable MN formulations, ie the 
limited loading capacity compared to other systems. This dissolvable MN prototype is an 
ideal DNA vaccine delivery system encompassing a high payload within the device itself, 
allowing decreased storage requirements and greater functionality.  
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Treatment Transfection Efficacy in NCTC-929 
(%) 
Transfection Efficacy Relative to F-NPs 
(%) 
Manufacturing Method Microneedle Loading (µg) 
F-NP 61.4 100 N/A N/A 
L-NP 58.1 94.6 N/A N/A 
L-NP - T 19.0 30.9 N/A N/A 
F-NP + PVA 36.8 59.9 1 17.7 
L-NP + PVA 47.7 77.7 2 57.3 
